Overview

Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients

Status:
Unknown status
Trial end date:
2018-12-15
Target enrollment:
Participant gender:
Summary
Patients at least 18 years of age will be enrolled in the study to assess the efficacy and tolerability of Picato gel in the treatment of molluscum contagiosum. Patients must have an immunocompromised condition due to taking immunosuppressive drugs or having an inherited disease affecting the immune system.
Phase:
Early Phase 1
Details
Lead Sponsor:
Center for Clinical Studies, Texas
Collaborator:
LEO Pharma